|
Objective: To investigate the non-ischemic heart failure, dilated cardiomyopathy disease (Heart failure, HF Atorvastatin calcium (Ale); dilated cardiomyopathy, DCM) patients with left ventricular ejection fraction (Left Ventricular Ejection Fraction LVEF), New York Heart Diseases Association (NewYork Heart Association, NYHA) functional class, blood C-reactive protein (C Reaction Protein, CRP), flow-mediated endothelium-dependent vasodilation (flow-mediated vasodilatation, FMD), plasma total cholesterol ( Total Cholesterol, TC), LDL (low density lipoprotien, LDL), Ale treatment of DCM clinical basis. Methods: 60 patients with DCM selected are from the People's Hospital of Luzhou City of Cardiology hospital from June 2008 to February 2010 DCM HF patients, aged 42-83 years old, were randomly divided into Ale group, the control group, 30 cases in each Ale group of 18 males and 12 females, age (51.2 ± 9.1) years of age, and heart failure (4.1 ± 1.3) years, the control group, 19 men and 11 women, age (53.1 ± 8.4) years of age, the time of heart failure (3.8 ± 1.1) years. The general aspects of the two groups in age, gender, disease duration, blood pressure, heart rate, no significant differences (P gt; 0.05). Depending on the specific circumstances in the two groups of patients given conventional therapy (digitalis, ACEI, beta blockers, diuretics); Ale group Ale 10mg / d, plus 12 months of treatment, and 3 months respectively before treatment, treatment 12 months testing NYHA class, LVEF, CRP, FMD, TC, LDL. Indicators were one-way ANOVA, t test, χ2 test and Pearson correlation analysis. Results: The two groups of patients in age, gender, disease duration, blood pressure, heart rate, and conventional treatment no significant difference (P gt; 0.05). Hou Etuo 3 months and 12 months of treatment Laval statin group and control group, CRP, TC and LDL levels were reduced EF, NYHA functional class, and average FMD water of, but atorvastatin atorvastatin group CRP , TC and LDL levels decrease and increase in EF, NYHA classification and FMD levels significantly better than the control group (P lt; 0.05), respectively, for the three months of treatment, atorvastatin statin and control groups: CRP ( 3.52 ± 1.12mg / L VS 5.26 ± 1.92mg / L), EF (37.92 ± 6.09% VS 34.96 ± 4.96%), NYHA classification (2.26 ± 0.82 VS 2.70 ± 0.83), FMD (5.15 ± 0.86% VS 4.60 ± 0.58%), TC (3.13 ± 0.48 mmol / L VS 3.43 ± 0.58 mmol / L), LDL (2.85 ± 0.59 mmol / L VS3.24 ± 0.33 mmol / L), P lt; 0.05; 12 months of treatment A Torvald statin group and the control group: CRP (2.02 ± 1.33 mg / L VS 4.51 ± 1.26 mg / L), EF (49.33 ± 8.50% VS 36.26 ± 5.90%), NYHA classification (1.90 ± 0.0.75 VS 2.33 ± 0.88), FMD (7.01 ± 1.50% VS 4.62 ± 0.64%), TC (2.85 ± 0.47mmol / L VS 3.34 ± 0.45mmol / L), LDL (2.25 ± 0.41 mmol / L VS 3.20 ± 0.50mmol / L), P lt; 0.05. 2. atorvastatin atorvastatin group EF CRP levels showed a significant negative correlation (r = -0.517, P-value less than 0.01), EF and FMD level was significantly positively correlated (r = 0.707, P value of less than 0.01), while the EF and TC, LDL was zero; EF and CRP, FMD control group, TC, LDL level was zero correlation. Conclusion the: 1.DCM heart failure patients on the basis of conventional treatment with atorvastatin statins 10mg / d 3 months of treatment and treatment of 12 months can be significantly improved left ventricular function and endothelial function, lower blood CRP, TC LDL levels. Atorvastatin statins improve the cardiac function of patients with DCM may through reduce CRP, improve endothelial function to achieve, independent of the lipid-lowering outside.
|